Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
DMAC
$8.55
$
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Next Earnings
2026-02-25
Beta
1.084
Average Volume
Market Cap
Last Dividend
CIK
0001401040
ISIN
CA25253X2077
CUSIP
25253X207
CEO
Dietrich John Pauls
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
27
IPO Date
2012-08-03
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences | MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in three upcoming investment bank conferences. Details TD Cowen 46th Annual Healthcare Conference Boston, Massachusetts Fireside chat with Rick Pauls, CEO, and Julie Krop, M.D., Chief Medical Officer, on Monday, Mar. | Business Wire | 2026-02-24 09:23:00 |
| Leon Cooperman's Strategic Moves: Mr. Cooper Group Inc. Exits with -18.82% Impact | Insight into Leon Cooperman (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Leon Cooperman (Trades, Portfolio) recently submitted the 13F filing for the f | GuruFocus | 2026-02-17 11:03:00 |
| DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages | Shares of DiaMedica Therapeutics, Inc. (NASDAQ: DMAC - Get Free Report) have received a consensus rating of "Moderate Buy" from the six research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average | Defense World | 2026-02-07 04:46:44 |
| DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on January 15, 2026, it granted options to purchase an aggregate of 50,000 shares of DiaMedica's common stock to a newly hired non-executive employee whose employment commenced in December 2025. The stock options were a material inducement to the emplo. | Business Wire | 2026-01-16 17:00:00 |
| DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA | MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today announced completion of a productive in-person pre-IND meeting with the United States Food and Drug Administration (FDA) for a planned study evaluating DM199 in preeclampsia. Minutes from the meeting affirmed the FDA's request for one additional non-clinical, 1. | Business Wire | 2025-12-18 08:45:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-06 | 2026-02-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 8-K | 2026-01-05 | 2026-01-05 | View Filing |
| 8-K | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-08 | 2025-12-08 | View Filing |
| 4 | 2025-11-25 | 2025-11-25 | View Filing |
| S-8 | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| SC 13G/A | 2025-11-07 | 2025-11-07 | View Filing |
| 4 | 2025-11-03 | 2025-11-03 | View Filing |
| 3 | 2025-11-03 | 2025-11-03 | View Filing |
| SC 13G/A | 2025-10-15 | 2025-10-15 | View Filing |
| 4 | 2025-09-04 | 2025-09-04 | View Filing |
| SC 13G/A | 2025-09-04 | 2025-09-04 | View Filing |
| SC 13G | 2025-08-27 | 2025-08-27 | View Filing |
| EFFECT | 2025-08-25 | 2025-08-25 | View Filing |
| 424B2 | 2025-08-22 | 2025-08-22 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| S-3 | 2025-08-12 | 2025-08-12 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| EFFECT | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-08-06 | 2025-08-06 | View Filing |
| S-3 | 2025-08-01 | 2025-08-01 | View Filing |
| SC 13G/A | 2025-07-30 | 2025-07-30 | View Filing |
| SC 13G/A | 2025-07-30 | 2025-07-30 | View Filing |
| 4 | 2025-07-25 | 2025-07-25 | View Filing |
| 4 | 2025-07-25 | 2025-07-25 | View Filing |
| 4 | 2025-07-25 | 2025-07-25 | View Filing |
| D | 2025-07-25 | 2025-07-24 | View Filing |
| 8-K | 2025-07-21 | 2025-07-21 | View Filing |
| 8-K | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-06-03 | 2025-06-03 | View Filing |
| 4 | 2025-06-03 | 2025-06-03 | View Filing |
| 4 | 2025-06-03 | 2025-06-03 | View Filing |
| 4 | 2025-06-03 | 2025-06-03 | View Filing |
| 4 | 2025-06-03 | 2025-06-03 | View Filing |
| 4 | 2025-06-03 | 2025-06-03 | View Filing |
| 4 | 2025-06-03 | 2025-06-03 | View Filing |
| 4 | 2025-06-03 | 2025-06-03 | View Filing |
| 8-K | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-04-08 | 2025-04-08 | View Filing |
| ARS | 2025-03-28 | 2025-03-28 | View Filing |
| DEFA14A | 2025-03-28 | 2025-03-28 | View Filing |
| DEF 14A | 2025-03-28 | 2025-03-28 | View Filing |
| 10-K | 2025-03-17 | 2025-03-17 | View Filing |
| 8-K | 2025-03-17 | 2025-03-17 | View Filing |
| 8-K | 2025-03-06 | 2025-03-06 | View Filing |
| 4 | 2025-02-24 | 2025-02-24 | View Filing |
| 3 | 2025-02-24 | 2025-02-24 | View Filing |
| 8-K | 2025-02-24 | 2025-02-24 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 10-Q | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-08-07 | 2024-08-07 | View Filing |
| 10-Q | 2024-08-07 | 2024-08-07 | View Filing |
| EFFECT | 2024-07-19 | 2024-07-19 | View Filing |
| 424B3 | 2024-07-18 | 2024-07-18 | View Filing |
| S-3 | 2024-07-10 | 2024-07-10 | View Filing |
| SC 13G | 2024-07-08 | 2024-07-08 | View Filing |
| D | 2024-07-02 | 2024-07-02 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| 8-K | 2024-06-26 | 2024-06-26 | View Filing |
| 8-K | 2024-06-26 | 2024-06-26 | View Filing |
| 4 | 2024-06-03 | 2024-06-03 | View Filing |
| 4 | 2024-06-03 | 2024-06-03 | View Filing |
| 4 | 2024-06-03 | 2024-06-03 | View Filing |
| 4 | 2024-06-03 | 2024-06-03 | View Filing |
| 4 | 2024-06-03 | 2024-06-03 | View Filing |
| 4 | 2024-06-03 | 2024-06-03 | View Filing |
| 4 | 2024-06-03 | 2024-06-03 | View Filing |
| 4 | 2024-06-03 | 2024-06-03 | View Filing |
| 4 | 2024-06-03 | 2024-06-03 | View Filing |
| 4 | 2024-06-03 | 2024-06-03 | View Filing |
| S-8 | 2024-05-24 | 2024-05-24 | View Filing |
| 8-K | 2024-05-23 | 2024-05-23 | View Filing |
| 10-Q | 2024-05-08 | 2024-05-08 | View Filing |
| 8-K | 2024-05-08 | 2024-05-08 | View Filing |
| 8-K | 2024-04-10 | 2024-04-10 | View Filing |
| EFFECT | 2024-04-10 | 2024-04-10 | View Filing |
| ARS | 2024-04-04 | 2024-04-04 | View Filing |
| DEFA14A | 2024-04-04 | 2024-04-04 | View Filing |
| DEF 14A | 2024-04-04 | 2024-04-04 | View Filing |
| S-3 | 2024-03-21 | 2024-03-21 | View Filing |
| 10-K | 2024-03-19 | 2024-03-19 | View Filing |
| 8-K | 2024-03-19 | 2024-03-19 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Williams PercentR Strategy | 62.43% | 1.01 | 323 | 0.06 | 0.16 | 48.58 |
| Bollinger Bands Strategy | 51.63% | 0.97 | 71 | 0.07 | 0.15 | 37.79 |
| Mean Reversion Strategy | 42.47% | 1.01 | 515 | 0.04 | 0.11 | 28.63 |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxx | xxxx% | xxxx | xxx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | x | x | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |